Actinium Pharmaceuticals (ATNM) Shares Gap Up to $0.31

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) gapped up prior to trading on Monday . The stock had previously closed at $0.33, but opened at $0.31. Actinium Pharmaceuticals shares last traded at $0.28, with a volume of 12067 shares changing hands.

Several research firms recently commented on ATNM. Zacks Investment Research raised Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a report on Monday, April 1st. Maxim Group reaffirmed a “buy” rating and issued a $3.00 price target on shares of Actinium Pharmaceuticals in a report on Wednesday, March 20th. Finally, Oppenheimer set a $5.00 price target on Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, February 26th. Five equities research analysts have rated the stock with a buy rating, Actinium Pharmaceuticals has a consensus rating of “Buy” and an average price target of $3.50.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its earnings results on Tuesday, March 19th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06).

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc increased its stake in Actinium Pharmaceuticals by 6.4% during the third quarter. Vanguard Group Inc now owns 2,575,754 shares of the biotechnology company’s stock worth $1,909,000 after acquiring an additional 154,403 shares during the last quarter. Vanguard Group Inc. increased its stake in Actinium Pharmaceuticals by 6.4% during the third quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock worth $1,909,000 after acquiring an additional 154,403 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Actinium Pharmaceuticals by 23.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,031,210 shares of the biotechnology company’s stock worth $399,000 after acquiring an additional 198,480 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in Actinium Pharmaceuticals by 69.3% during the first quarter. Oppenheimer & Co. Inc. now owns 175,512 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 71,840 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Actinium Pharmaceuticals by 69.9% during the first quarter. Renaissance Technologies LLC now owns 139,347 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 57,335 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This story was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/22/actinium-pharmaceuticals-atnm-shares-gap-up-to-0-31.html.

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Read More: How Do Mutual Funds Work?

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.